



## **HEALTH AND WELLBEING BOARD**

### **21<sup>st</sup> March 2019**

# **ITEM 14**

Report sponsor: Cate Edwynn, Director of Public Health  
Report author: Alison Wynn, Assistant Director of Public Health

## **Pharmacy Consolidation Application – PCC-201718-29 B.J. Wilson - Sinfin**

### **Purpose**

- 1.1 The Health and Wellbeing Board (HWB) was notified on 1 December of an application to consolidate two community pharmacies in Sinfin onto one site: to consolidate onto the site at 18-20 Sinfin District Centre, Sinfin, Derby DE24 3ND of B. J. Wilson Ltd already at that site and B. J. Wilson Ltd currently at 430 Stenson Road, Derby DE23 1LH.
- 1.2 The purpose of this report is to update the HWB on the response made to NHS England on behalf of the HWB in relation to this application.

### **Recommendations**

- 2.1 To note the analysis and process undertaken to support the HWB in determining whether the proposed removal of premises from the pharmaceutical list would or would not create a gap in pharmaceutical services.
- 2.2 To note that the representation of Derby City HWB to PCC, NHS England was that the consolidation of the two sites would not create a gap in pharmaceutical services that could be met by a routine application (a) to meet a current or future need for pharmaceutical services, or (b) to secure improvements, or better access, to pharmaceutical services. This representation was made by the Chair of the HWB using their delegated decision making powers.

### **Reason**

- 3.1 To meet the duty of the HWB to make representations on consolidation applications to NHS England within the required timescale.

### **Supporting information**

- 4.1 The HWB received a letter on 3 December (dated 1 December) from NHS England notifying of an application for the consolidation of two pharmacies onto one site in Sinfen. The HWB is required to make representations to NHS England on consolidation applications within 45 days of notification.
- 4.2 Representations from the HWB to NHS England on this consolidation application were required to be made by 15 January.
- 4.3 To support appropriate representation, the following process has been undertaken:
- Analysis undertaken relating to key considerations such as access and availability; choice; services provided; any future developments in the area; notable risks.
  - Analysis and draft recommendation (as per Appendix 1) circulated to all HWB members, elected members of the relevant ward, local authority and NHS commissioner of pharmaceutical services.
  - Feedback from the stakeholders was collated, see Appendix 2. The feedback received broadly supported the draft recommendation that the proposed consolidation would not create a gap in pharmaceutical services.
  - Analysis and feedback provided to the HWB Chair for consideration.
- 4.4 A letter confirming that, in the opinion of the HWB, the proposed consolidation of the two sites would not create a gap in pharmaceutical services was sent to NHS England on behalf of the HWB on 11<sup>th</sup> January 2019. A copy of this letter is attached in Appendix 3 for information.
- 4.5 The Pharmaceutical Services Regulations Committee (PSRC) considered this consolidation application at the meeting held on Friday 15 February 2019. The Committee approved the application.
- 4.6 NHS England confirmed its decision by letter on 15 February 2019. This is attached as Appendix 4 for information.

## **Public/stakeholder engagement**

5.1 None.

## **Other options**

6.1 Ideally pharmacy consolidation applications would be considered at a meeting of the HWB. Due to the 45 day response time requirement, however, this option is not viable.

## **Financial and value for money issues**

7.1 There are no specific financial or value for money issues for the HWB.

## **Legal implications**

8.1 The NHS (Pharmaceutical Services, Charges and Prescribing) (Amendment) Regulations 2016 requires the HWB to make representations on consolidation applications to NHS England. The process proposed in this paper is to support the HWB in meeting its statutory duty in this regard.

## **Other significant implications**

9.1 No other implications noted.

**This report has been approved by the following people:**

<b>Role</b>	<b>Name</b>	<b>Date of sign-off</b>
<b>Legal</b>		
<b>Finance</b>	Alison Parkin, Head of Finance – People Service's	20/12/2018
<b>Service Director(s)</b>		
<b>Report sponsor</b>	Cate Edwynn, Director of Public Health	
<b>Other(s)</b>		

